Regulators of Metastasis-Related Signalling Targets in Cancer Cells
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 461
Special Issue Editors
Interests: breast cancer; metastasis; cytoskeletal; PTEN; PI3K; circulating tumor cells (CTCs)
Interests: breast cancer; transcriptional regulation; angiogenesis; drug development
Special Issues, Collections and Topics in MDPI journals
Interests: cancer biology; structural biology; biophysics; drug discovery/development; high-throughput screening; cell signaling; cellular therapeutics; biometals
Special Issue Information
Dear Colleagues,
This Special Issue, "Regulators of Metastasis related Signalling Targets in Cancer Cells," will focus on cancer cell metastasis regulation and molecular targets for preventing tumor metastasis.
Metastasis causes more than 90% of cancer deaths. However, approved drugs or therapies specifically targeting metastasis have yet to be developed since metastasis is a highly complex, multistep process. During metastasis, primary tumor cells intravasate into, and disseminate within, the bloodstream and/or lymphatics, temporarily survive within the new inhospitable environment, and extravasate into secondary locations with mitogenic signals for regrowth. Tumor cells undergoing metastasis aberrantly regulate intracellular signaling molecules, cytoskeleton components, cell–cell interactions, and release of extracellular enzymes or signaling molecules. While multiple mechanisms responsible for promoting metastasis continue to be elucidated, there are still many unanswered questions regarding effective targets for metastatic inhibition.
We would like to invite authors to submit research and review articles that focus on metastasis biology and potential therapeutics to prevent it.
Dr. Michele I. Vitolo
Guest Editor
Prof. Dr. Antonino Passaniti
Dr. Paul T. Wilder
Co-Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PI3K pathway and/or MAPK pathway and metastasis
- Extracellular mediators of metastasis
- Role of cytoskeleton components in metastasis
- Drugs and/or molecular targets for metastatic inhibition
- Novel master regulators or key mediators of metastatic progression
- New models of cancer metastasis
